Provided by Tiger Trade Technology Pte. Ltd.

EyePoint

5.32
-0.0800-1.48%
Post-market: 5.30-0.0200-0.38%19:57 EDT
Volume:8.19M
Turnover:42.51M
Market Cap:458.65M
PE:-1.41
High:5.50
Open:5.48
Low:4.98
Close:5.40
52wk High:19.11
52wk Low:3.95
Shares:86.21M
Float Shares:64.06M
Volume Ratio:0.47
T/O Rate:12.78%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.7642
EPS(LYR):-3.1667
ROE:-148.70%
ROA:-74.85%
PB:2.76
PE(LYR):-1.68

Loading ...

EyePoint grants inducement stock options for 39,700 shares at $12.08 each

Reuters
·
Jun 16

EyePoint Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Jun 16

EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire
·
Jun 16

Analyst Reiterates Buy on EyePoint, Sees Durability as Key Differentiator with Price Target Maintained at $43

TIPRANKS
·
Jun 12

EyePoint’s CAPRI Phase 3 Trial Targets Long-Acting Relief in Diabetic Eye Disease

TIPRANKS
·
Jun 04

Phase 3 DURAVYU Safety Green Light Might Change The Case For Investing In EyePoint (EYPT)

Simply Wall St.
·
May 22

EyePoint Pharma Bets Big on DURAVYU Pivotal Data

TIPRANKS
·
May 20

EyePoint management joins Stifel Virtual Ophthalmology Forum fireside chat

Reuters
·
May 19

EyePoint Announces Participation at Upcoming Investor Conferences

GlobeNewswire
·
May 19

EyePoint grants inducement stock options for 158,100 shares at $12.35 each

Reuters
·
May 18

EyePoint Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
May 18

EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire
·
May 18

EyePoint receives positive DSMC recommendation for Duravyu Phase 3 trials

TIPRANKS
·
May 14

EyePoint's late-stage eye drug trials to continue after safety panel review

Reuters
·
May 14

EyePoint Pharmaceuticals Says Phase 3 Eye Drug Trials Clear Safety Review

MT Newswires Live
·
May 14

EyePoint Advances DURAVYU Phase 3 Wet AMD Program

TIPRANKS
·
May 14

EyePoint Inc - Dsmc Recommends Phase 3 Duravyu Wet Amd Trials Continue With No Modifications

THOMSON REUTERS
·
May 14

EyePoint Inc - Interim Phase 3 Data Shows Continued Favorable Safety Profile for Duravyu

THOMSON REUTERS
·
May 14

EyePoint Announces Third Consecutive Positive Dsmc Recommendation for Phase 3 Wet Amd Trials for Duravyu™, Building Confidence Ahead of Mid-2026 Topline Data

THOMSON REUTERS
·
May 14

EyePoint Pharmaceuticals Is Maintained at Outperform by RBC Capital

Dow Jones
·
May 08